Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
REPL

REPL - Replimune Group Inc Stock Price, Fair Value and News

8.37USD-1.09 (-11.52%)Market Closed

Market Summary

REPL
USD8.37-1.09
Market Closed
-11.52%

REPL Alerts

  • 4 major insider sales recently.

REPL Stock Price

View Fullscreen

REPL RSI Chart

REPL Valuation

Market Cap

514.0M

Price/Earnings (Trailing)

-2.38

Price/Sales (Trailing)

22.01

EV/EBITDA

-2.33

Price/Free Cashflow

-2.77

REPL Price/Sales (Trailing)

REPL Profitability

EBT Margin

-922.21%

Return on Equity

-57.62%

Return on Assets

-44.25%

Free Cashflow Yield

-36.08%

REPL Fundamentals

REPL Revenue

Revenue (TTM)

23.4M

Rev. Growth (Yr)

-7.51%

Rev. Growth (Qtr)

-4.42%

REPL Earnings

Earnings (TTM)

-215.8M

Earnings Growth (Yr)

-11.8%

Earnings Growth (Qtr)

-7.74%

Breaking Down REPL Revenue

Last 7 days

32.9%

Last 30 days

40.8%

Last 90 days

10.8%

Trailing 12 Months

-59.7%

How does REPL drawdown profile look like?

REPL Financial Health

Current Ratio

10.72

Debt/Equity

0.12

Debt/Cashflow

-4.14

REPL Investor Care

Shares Dilution (1Y)

6.30%

Diluted EPS (TTM)

-3.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202423.4M000
202310.0M15.8M20.8M23.8M
20221.7M1.3M1.7M4.3M
20212.8M2.9M2.9M2.4M
20203.1M3.1M3.3M2.9M
20192.8M3.3M3.2M2.6M
20182.3M2.1M2.1M3.0M
20170000

Tracking the Latest Insider Buys and Sells of Replimune Group Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 07, 2024
xynos konstantinos
sold
-119,108
7.5
-15,881
chief medical officer
May 16, 2024
sarchi christopher
sold
-28,700
6.47
-4,436
chief commercial officer
May 16, 2024
astley-sparke philip
sold
-245,394
6.47
-37,928
executive chairman
May 16, 2024
coffin robert
sold
-74,172
6.47
-11,464
-
May 16, 2024
love colin
sold
-113,969
6.47
-17,615
chief operating officer
May 16, 2024
xynos konstantinos
sold
-82,389
6.47
-12,734
chief medical officer
May 16, 2024
patel sushil
sold
-261,310
6.47
-40,388
chief executive officer
May 16, 2024
schwendenman andrew
sold
-29,736
6.47
-4,596
chief accounting officer

1–10 of 50

Which funds bought or sold REPL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
sold off
-100
-2,023
-
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
72.81
38,471
96,471
0.01%
May 17, 2024
Artal Group S.A.
sold off
-100
-4,215,000
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-7.22
-33,726
300,819
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-35.19
-763,433
1,289,370
-%
May 16, 2024
COMERICA BANK
added
5,307
6,067
6,184
-%
May 15, 2024
Voya Investment Management LLC
reduced
-13.33
-26,021
136,611
-%
May 15, 2024
MARSHALL WACE, LLP
reduced
-82.88
-680,844
135,466
-%
May 15, 2024
Virtus ETF Advisers LLC
reduced
-6.42
-9,360
91,218
0.05%
May 15, 2024
Redmile Group, LLC
reduced
-3.5
-2,110,160
30,474,000
1.12%

1–10 of 44

Are Funds Buying or Selling REPL?

Are funds buying REPL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own REPL
No. of Funds

Unveiling Replimune Group Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2024
state street corp
10.57%
6,486,696
SC 13G/A
Apr 10, 2024
price t rowe associates inc /md/
10.7%
6,548,930
SC 13G/A
Feb 14, 2024
forbion capital fund iii cooperatief u.a.
8.7%
5,191,621
SC 13G/A
Feb 14, 2024
price t rowe associates inc /md/
9.9%
5,855,625
SC 13G/A
Feb 14, 2024
omega fund iv, l.p.
5.5%
3,249,991
SC 13G/A
Feb 14, 2024
redmile group, llc
7.4%
4,604,483
SC 13G/A
Feb 09, 2024
morgan stanley
7.4%
4,388,888
SC 13G
Jan 26, 2024
blackrock inc.
7.7%
4,538,487
SC 13G/A
Jan 25, 2024
state street corp
8.65%
5,111,521
SC 13G
Jan 10, 2024
baker bros. advisors lp
16.2%
9,545,336
SC 13G/A

Recent SEC filings of Replimune Group Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
8-K
Current Report
Jun 10, 2024
4
Insider Trading
Jun 07, 2024
144
Notice of Insider Sale Intent
Jun 06, 2024
8-K
Current Report
Jun 03, 2024
8-K
Current Report
May 23, 2024
144
Notice of Insider Sale Intent
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading

Peers (Alternatives to Replimune Group Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
13.11% 15.14%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.19% -19.39%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
5.74% -10.79%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
9.90% 2.05%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
0.17% 71.70%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
3.28% -53.81%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-6.27% -10.41%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
15.67% -25.01%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.65% 94.95%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
22.84% 567.64%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-17.34% 57.33%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Replimune Group Inc News

Latest updates
MarketBeat5 hours ago
Simply Wall St22 May 202407:00 am
InvestorPlace6 months ago

Replimune Group Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-4.4%5,434,5005,686,0006,049,0006,186,0005,876,0002,675,0001,112,000343,000131,00087,000725,000788,000816,000550,000755,000686,000859,000951,000620,000687,000325,500
Operating Expenses3.9%58,755,00056,540,00063,831,00055,648,00052,995,00041,630,00041,579,00040,876,00031,988,00029,698,00029,247,00027,381,00022,184,00020,275,00019,663,00017,833,00016,385,00016,664,00012,242,00010,907,0007,826,000
  S&GA Expenses18.1%16,176,50013,693,00014,730,00015,211,00015,041,00011,369,00012,745,00011,398,00010,252,00010,345,0009,345,0008,827,0005,959,0005,953,0005,613,0005,676,0005,197,0004,716,0004,074,0003,450,0002,410,500
  R&D Expenses-0.6%42,578,50042,847,00049,101,00040,437,00037,954,00030,261,00028,834,00029,478,00021,736,00019,353,00019,902,00018,554,00016,225,00014,322,00014,050,00012,157,00011,188,00011,948,0008,168,0007,457,0005,415,500
EBITDA Margin-4.7%-8.91-8.52-9.22-11.08-16.95-26.90-69.16-90.04-66.95------------
Interest Expenses39.8%1,414,5001,012,000955,0001,115,0001,022,000941,000------1,000247,000286,000284,000-834,000195,000--
Income Taxes-115.8%-79,000500,000-200,000201,000288,000----55,00012,000-----------
Earnings Before Taxes-8.9%-55,140,000-50,647,000-60,245,000-49,354,000-48,951,000-39,690,000-43,102,000-42,253,000-------------
EBT Margin-4.9%-9.22-8.79-9.54-11.43-17.39-27.70-70.55-91.79-68.19------------
Net Income-7.7%-55,075,000-51,120,000-60,044,000-49,555,000-49,261,500-39,690,000-43,102,000-42,253,000-31,696,000-29,674,000-29,355,000-27,311,000-21,499,000-21,783,000-20,095,000-17,493,000-15,789,000-16,189,000-11,139,000-9,508,000-6,656,000
Net Income Margin-4.7%-9.24-8.82-9.55-11.46-17.42-36.79-87.71-103-68.20-44.64-34.72-31.17---------
Free Cashflow2.0%-46,166,000-47,123,000-44,039,000-49,037,000-33,047,000-29,144,000-33,606,000-34,523,000-23,709,000-18,813,000-23,389,000-18,605,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-8.5%488533562604647679436459461485503524543559314330234250151144154
  Current Assets-9.5%434479508550593624379402404428444465484499252268174191118128141
    Cash Equivalents-23.8%74.0098.0076.0010614720891.0011410813416219418432645.0010661.0063.0065.0040.0027.00
  Net PPE10.7%10.009.008.008.007.008.008.008.008.007.007.007.007.007.007.007.007.006.004.001.0012.00
Liabilities1.6%11311197.0090.0091.0083.0052.0049.0050.0048.0046.0045.0044.0043.0053.0052.0050.0053.0031.0013.0016.00
  Current Liabilities4.6%40.0039.0040.0032.0034.0026.0024.0020.0021.0018.0017.0015.0015.0013.0013.0012.0012.0014.0012.0013.0010.00
  Long Term Debt0.8%45.0044.0029.0029.0029.0028.00--------10.0010.0010.0010.0010.00--
    LT Debt, Non Current-45.00---29.00----------------
Shareholder's Equity-11.2%375422465514555595384410411438457479499516261278184198121130138
  Retained Earnings-8.5%-701-646-595-535-485-436-396-353-311-279-249-220-193-171-149-129-112-96.51-80.32-69.18-59.77
  Additional Paid-In Capital0.7%1,0711,0631,0551,0451,0351,028778763723717707700692688412409297295202200199
Shares Outstanding0.0%61.0061.0059.0059.0057.0058.0054.0054.0047.0052.0052.0052.00---------
Float---606---487---620-500---178----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations2.0%-46,166-47,123-43,590-48,588-32,796-28,589-33,210-33,455-22,557-18,348-22,961-18,314-16,128-12,992-17,179-15,090-11,262-15,735-19,973-13,582-6,033
  Share Based Compensation-3.8%7,9248,2409,1158,8466,9227,0236,9927,1945,7735,9186,3136,2503,4723,0492,8012,4681,8062,3441,7811,810907
Cashflow From Investing-57.0%23,20153,95612,6837,361-22,752-125,10136.005,315-4,326-13,420-11,05226,992-126,27331,421-44,798-49,1267,841-65,20925,32426,81110,474
Cashflow From Financing-100.9%-13014,8704381,105-77.00271,4357,42332,5223593,9691,1501,120785262,198-35.00109,51434.0090,3649,75018.0041.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

REPL Income Statement

2024-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 174,963$ 126,527
Selling, general and administrative59,81050,553
Total operating expenses234,773177,080
Loss from operations(234,773)(177,080)
Other income (expense):  
Research and development incentives1,9202,914
Investment income23,35610,006
Interest expense on finance lease liability(2,163)(2,197)
Interest expense on debt obligations(4,497)(1,963)
Other income (expense)771(5,676)
Total other income, net19,3873,084
Loss before income taxes(215,386)(173,996)
Income tax provision408288
Net loss$ (215,794)$ (174,284)
Earnings Per Share, Basic$ (3.24)$ (2.99)
Net loss per share attributable to common stockholders, diluted (in dollars per share)$ (3.24)$ (2.99)
Weighted average common shares outstanding, basic (in shares)66,569,89458,213,010
Weighted average common shares outstanding, diluted (in shares)66,569,89458,213,010

REPL Balance Sheet

2024-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Mar. 31, 2023
Current assets:  
Cash and cash equivalents$ 74,457$ 146,590
Short-term investments346,211436,796
Research and development incentives receivable4,9222,939
Prepaid expenses and other current assets8,0776,278
Total current assets433,667592,603
Property, plant and equipment, net10,4837,479
Restricted cash1,7001,636
Right-to-use asset – operating leases4,6355,208
Right-to-use asset – financing leases37,23739,665
Total assets487,722646,591
Current liabilities:  
Accounts payable2,5785,364
Accrued expenses and other current liabilities33,98124,704
Operating lease liabilities, current1,1611,118
Financing lease liabilities, current2,7182,639
Total current liabilities40,43833,825
Operating lease liabilities, non-current3,7714,389
Financing lease liabilities, non-current23,41023,965
Long term debt, net of discount44,80928,648
Other liabilities, non-current786472
Total liabilities113,21491,299
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2024 and March 31, 2023; 61,415,105 and 56,676,313 shares issued and outstanding as of March 31, 2024 and March 31, 2023, respectively6157
Additional paid-in capital1,070,8741,034,994
Accumulated deficit(701,282)(485,488)
Accumulated other comprehensive income (loss)4,8555,729
Total stockholders’ equity374,508555,292
Total liabilities and stockholders’ equity$ 487,722$ 646,591
REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
 CEO
 WEBSITEreplimune.com
 INDUSTRYBiotechnology
 EMPLOYEES284

Replimune Group Inc Frequently Asked Questions


What is the ticker symbol for Replimune Group Inc? What does REPL stand for in stocks?

REPL is the stock ticker symbol of Replimune Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Replimune Group Inc (REPL)?

As of Thu Jun 13 2024, market cap of Replimune Group Inc is 580.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of REPL stock?

You can check REPL's fair value in chart for subscribers.

What is the fair value of REPL stock?

You can check REPL's fair value in chart for subscribers. The fair value of Replimune Group Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Replimune Group Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for REPL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Replimune Group Inc a good stock to buy?

The fair value guage provides a quick view whether REPL is over valued or under valued. Whether Replimune Group Inc is cheap or expensive depends on the assumptions which impact Replimune Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REPL.

What is Replimune Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, REPL's PE ratio (Price to Earnings) is -2.69 and Price to Sales (PS) ratio is 24.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REPL PE ratio will change depending on the future growth rate expectations of investors.